Clinical Trial Update: A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of chemotherapy, trastuzumab, and RAD001 (everolimus) for HER2-positive breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Everolimus (everolimus)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: University of Kansas | Conditions: Breast Cancer | Phase 2 | Status: WITHDRAWN